US2011250292A1PendingUtilityA1

Composition for improving radiotherapy for cancer

40
Assignee: CHONJISAN CO LTDPriority: Dec 16, 2008Filed: Nov 30, 2009Published: Oct 13, 2011
Est. expiryDec 16, 2028(~2.4 yrs left)· nominal 20-yr term from priority
Inventors:Ill Ju BaeSae-Gwang Park
A61P 35/00A61K 33/36A61K 41/0038
40
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Disclosed is a composition for improving radiotherapy for cancer, containing tetra-arsenic oxide (As 4 O 6 ) as an active ingredient. The disclosed composition for improving radiotherapy for cancer improves the efficiency of radiotherapy, and thus reduces side effects caused by the high-dose radiation. The disclosed composition uses tetra-arsenic oxide, the safety of which is proven, from among conventional arsenic compound derivatives, to prevent side effects caused by arsenic trioxide, taxol, cisplatin, fluorouracil, leuprolide, or the like, which are known as conventional radiosensitizers.

Claims

exact text as granted — not AI-modified
1 . A composition for improving radiotherapy on cancer, which comprises tetra-arsenic oxide As 4 O 6  as an active ingredient. 
     
     
         2 . The composition as claimed in  claim 1 , which is administered before or after irradiation. 
     
     
         3 . The composition as claimed in  claim 1 , which is formulated in oral dosage formulations. 
     
     
         4 . The composition as claimed in  claim 3 , wherein the oral dosage formulations comprise liquid formulation, suspension, powders, granules, tablets, capsules, pills, or extracts. 
     
     
         5 . The composition as claimed in  claim 2 , which is formulated in oral dosage formulations. 
     
     
         6 . A method for improving an radiotherapy effect on cancer, comprising administering a composition comprising tetra-arsenic oxide As 4 O 6  in a radiosensitizing amount to a cancer patient during, before or after radiotherapy. 
     
     
         7 . The method of  claim 6 , wherein the composition is administered on or after irradiation. 
     
     
         8 . The method of  claim 6 , wherein the composition is orally administered. 
     
     
         9 . The method of  claim 6 , wherein the amount of tetra-arsenic oxide As 4 O 6  is 0.1 to 10 mg/kg/day. 
     
     
         10 . The method of  claim 6 , wherein the composition is administered once a day or multiple times a day.

Join the waitlist — get patent alerts

Track US2011250292A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.